摘要
目的探讨玻璃体内注射雷珠单抗治疗增生性糖尿病视网膜病变的疗效及安全性。方法选取我院收治的160例增生性糖尿病视网膜病变作为研究对象,随机分为对照组和观察组,每组各80例。对照组使用玻璃体切除术治疗,观察组采用玻璃体内注射雷珠单抗治疗,观察比较两组手术时间、术中出血量及治疗效果,以及术后3个月的最佳矫正视力、术后并发症等。结果观察组手术时间、术中出血量及手术过程中出现的大出血事件显著低于对照组(P<0.05),治疗结果的优良率显著高于对照组(P<0.05)。观察组术后3个月的最佳矫正视力显著优于对照组(P<0.05),而术后感染及术后再出血的发生率显著低于对照组(P<0.05)。结论雷珠单抗玻璃体内注射治疗增生性糖尿病视网膜病变,能够显著降低患者手术时间和术中出血量,并且有着更佳的最佳矫正视力,且术后感染及术后再出血的发生率低,值得临床推广使用。
Objective To investigate the curative effects of intravitreal injection with ranibizumab on proliferative diabetic retinopathy and its safety. Methods 160 cases of proliferative diabetic retinopathy were selected as research objects and randomly divided into control group and observation group, with 80 cases in each group. The control group was treated by vitrectomy, while the observation group was treated by intravitreal injection with ranibizumab. Observation and comparison were made in the operation time,intraoperative blood loss, and the therapeutic effects, the best corrected visual acuity three months after the operation, and postoperative complications between the two groups. Results The operation time, intraoperative blood loss, and the incidence of major bleeding events during the operation in the observation group were significantly shorter and lower than those in the control group（P 0.05）. The excellence rate of the observation group was significantly higher than that of the control group（P 0.05）. The best corrected visual acuity three months after the operation in the observation group was significantly superior to that in the control group（P 0.05）, and the incidence of postoperative infection and bleeding in the former group was significantly lower than that in the latter group（P 0.05）. Conclusion Intravitreal injection with ranibizumab for the treatment of proliferative diabetic retinopathy can significantly reduce the operation time and intraoperative blood loss and provide patients a superior best corrected visual acuity. The probability of postoperative infection and bleeding is low. It is worthy of clinical promotion.
出处
《西南国防医药》
CAS
2016年第5期508-510,共3页
Medical Journal of National Defending Forces in Southwest China
